Table 3 Coefficient estimates across the IPD-AgD NMA of all models considered in the analysis for viral suppression at 48 weeks as an outcome
Analyses | Model | ß1,1 Median (95% CrI) | ß1,2 Median (95% CrI) | ß1,3 Median (95% CrI) | ß0,1 Median (95% CrI) | ß0,2 Median (95% CrI) | ß0,3 Median (95% CrI) |
|---|---|---|---|---|---|---|---|
AgD NMA meta-regression – CD4 | Fixed | 0.096 (−0.039, 0.216) | – | – | – | – | – |
AgD NMA meta-regression – HIV RNA | Fixed | 0.009 (− 0.368, 0.377) | – | – | – | – | – |
AgD NMA meta-regression – Male | Fixed | 0.041 (− 0.947, 1.035) | – | – | – | – | – |
One-stage IPD-AgD NMA – CD4 + HIV RNA + Male | Fixed | 0.144 (0.015, 0.272) | −0.031 (− 0.363, 0.296) | −0.237 (− 0.957, 0.429) | −0.779 (−3.481, 1.729) | 0.256 (−9.87, 7.315) | −7.108 (−20.194, 17.658) |
One-stage IPD-AgD NMA – CD4 + Male | Fixed | 0.135 (0.011, 0.264) | − 0.019 (− 0.338, 0.303) | – | 0.174 (− 2.918, 2.76) | −1.272 (−6.477, 3.456) | – |
One-stage IPD-AgD NMA – CD4 + HIV RNA | Fixed | 0.149 (0.035, 0.269) | −0.229 (− 0.945, 0.427) | – | −0.413 (− 2.778, 1.985) | −2.913 (− 10.851, 4.943) | – |
One-stage IPD-AgD NMA – HIV RNA + Male | Fixed | −0.195 (− 0.486, 0.097) | −0.105 (− 0.791, 0.539) | – | 8.999 (− 0.415, 15.519) | −19.637 (− 32.557, − 6.818) | – |
One-stage IPD-AgD NMA – CD4 | Fixed | 0.139 (0.028, 0.251) | – | – | 0.351 (− 1.398, 2.058) | – | – |
One-stage IPD-AgD NMA – HIV RNA | Fixed | −0.182 (− 0.468, 0.104) | – | – | −0.500 (− 4.586, 3.167) | – | – |
One-stage IPD-AgD NMA – Male | Fixed | − 0.014 (− 0.674, 0.607) | – | – | 1.347 (− 10.007, 6.357) | – | – |